ITEM VIEW

Antiretroviral drugs for preventing mother-to-child transmission of HIV: A review of potential effects on HIV-exposed but uninfected children

dc.contributor.authorHeidari S.
dc.contributor.authorMofenson L.
dc.contributor.authorCotton M.F.
dc.contributor.authorMarlink R.
dc.contributor.authorCahn P.
dc.contributor.authorKatabira E.
dc.date.accessioned2011-10-13T16:58:20Z
dc.date.available2011-10-13T16:58:20Z
dc.date.issued2011
dc.identifier.citationJournal of Acquired Immune Deficiency Syndromes
dc.identifier.citation57
dc.identifier.citation4
dc.identifier.citationhttp://www.scopus.com/inward/record.url?eid=2-s2.0-79959951684&partnerID=40&md5=bb5001936513f677d920b3cc000a66b4
dc.identifier.issn15254135
dc.identifier.other10.1097/QAI.0b013e318221c56a
dc.identifier.urihttp://hdl.handle.net/10019.1/16686
dc.description.abstractThe provision of antiretroviral drugs for the prevention of mother-to-child HIV transmission has been rising sharply in low- and middle-income countries. Changes to the World Health Organization guidelines support further extension of these programs. The result will be a greatly expanded population of HIV-exposed but uninfected children with substantial exposure to antiretroviral drugs, both in utero and while breastfeeding. There are limited data on possible toxicities in this burgeoning population, and the large number of confounding factors limits any conclusions. Although the evidence on birth defects and mitochondrial toxicity remains equivocal, considerable data link protease inhibitors to preterm delivery and low birth-weight. Transient hematologic toxicities are also likely. The drug impact later in life is an open question. Larger and longer cohort studies are necessary to properly balance the risks and benefits of large-scale infant exposure to antiretroviral agents. © 2011 by Lippincott Williams & Wilkins.
dc.subjectantiretroviral
dc.subjectchildhood growth and development
dc.subjectdrug complications
dc.subjectHIV-exposed uninfected infants
dc.subjectPMTCT
dc.subjectantiretrovirus agent
dc.subjectdidanosine
dc.subjectefavirenz
dc.subjectfolic acid antagonist
dc.subjectlamivudine
dc.subjectlopinavir
dc.subjectnevirapine
dc.subjectproteinase inhibitor
dc.subjectritonavir
dc.subjectRNA directed DNA polymerase inhibitor
dc.subjectstavudine
dc.subjectzalcitabine
dc.subjectzidovudine
dc.subjectanemia
dc.subjectanophthalmia
dc.subjectbirth defect
dc.subjectblood toxicity
dc.subjectbreast feeding
dc.subjecthuman
dc.subjectHuman immunodeficiency virus infection
dc.subjectlow birth weight
dc.subjectmeningomyelocele
dc.subjectmitochondrial toxicity
dc.subjectneural tube defect
dc.subjectneutropenia
dc.subjectpremature labor
dc.subjectprematurity
dc.subjectprenatal exposure
dc.subjectpriority journal
dc.subjectreview
dc.subjectvirus transmission
dc.titleAntiretroviral drugs for preventing mother-to-child transmission of HIV: A review of potential effects on HIV-exposed but uninfected children
dc.typeReview
dc.description.versionReview


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW